Synergistic Upregulation of Extracellular Vesicles and Cell-Free Nucleic Acids by Chloroquine and Temozolomide in Glioma Cell Cultures
Authors:
- Aleksander Emilov AleksandrovAAAleksander Emilov Aleksandrov
- Banko Ivaylov BankovBBBanko Ivaylov Bankov
- Vera Lyubchova DjeliovaVDVera Lyubchova Djeliova
- Georgi Georgiev AntovGeorgi Georgiev Antov
- Svetozar StoichevSSSvetozar Stoichev
- Roumyana Silvieva MironovaRMRoumyana Silvieva Mironova
- Dimitar Borisov IlievDIDimitar Borisov Iliev
Preprint
- 25 August 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Extracellular vesicles (EVs) secreted by glioblastoma multiforme and other types of cancer cells are key factors contributing to the aggressiveness of the disease and its resistance to therapy. Chloroquine (CHQ), a lysosomal inhibitor, has shown potential as an enhancer of temozolomide (TMZ) cytotoxicity against glioblastoma cells. Since both CHQ and TMZ are known to modulate EV secretion, we sought to investigate their potential interplay in this process. Simultaneous treatment of TMZ-sensitive (U87-MG) and TMZ-resistant (U138-MG) glioblastoma cells with TMZ and CHQ led to a synergistic upregulation of EV secretion. Although CHQ did not enhance the TMZ cytotoxicity in U87-MG cells, it synergized with the latter to upregulate the release of extracellular nucleic acids implicating activation of unconventional secretory pathways. Synergistic upregulation of the autophagy markers LC3B-II and p62 by CHQ and TMZ in both cells and EVs indicates secretory autophagy is likely involved in the observed unconventional secretion. Moreover, a significant enrichment of caveolin-1 in small EVs highlights their potential role in modulating tumor aggressiveness. The synergy in EV upregulation was not confined to the specific biological activity of TMZ and CHQ; similar effects were observed upon co-treatments with CHQ and etoposide (a topoisomerase inhibitor) and TMZ and Bafilomycin A1 (another lysosomal inhibitor). Heightened EV release was also observed in THP-1 monocytes and macrophages treated with Bafilomycin and TMZ, highlighting a broader, cell type-independent mechanism. These findings indicate that combined DNA damage and lysosomal inhibition synergistically stimulate secretory autophagy and EV release, potentially impacting the tumor microenvironment and driving disease progression.Keywords
All Related Versions
This publication has 52 references indexed in Scilit:
- Recruitment of DNA to tumor-derived microvesiclesCell Reports, 2022
- Reassessment of Exosome CompositionCell, 2019
- Temozolomide affects Extracellular Vesicles Released by Glioblastoma CellsBiochimie, 2018
- Caveolin‐1, cancer and therapy resistanceInternational Journal of Cancer, 2018
- Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in gliomaJournal of Neuro-Oncology, 2016
- PIKfyve inhibition increases exosome release and induces secretory autophagyCellular and Molecular Life Sciences, 2016
- Large Oncosomes in Human Prostate Cancer Tissues and in the Circulation of Mice with Metastatic DiseaseThe American Journal of Pathology, 2012
- Recent advances in the molecular understanding of glioblastomaJournal of Neuro-Oncology, 2012
- The brain tumor microenvironmentGlia, 2011
- A microgel electrophoresis technique for the direct quantitation of DNA damage and repair in individual fibroblasts cultured on microscope slidesMutation Research/Environmental Mutagenesis and Related Subjects, 1991